Company ProfilePremium

Invion Limited

Company Profile Analysis

Ticker: IVX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Invion Limited - Company showcase

Year Founded & Workforce

2000

Invion Limited logo

Invion Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Invion Limited Overview

Invion Limited is a Melbourne-based, micro-capitalisation clinical-stage life-sciences company developing Photosoft™, a next-generation photodynamic therapy (NGPDT) platform comprising a library of more than 300 photosensitiser compounds. Its lead candidate, INV043, is a light-activated photosensitiser being studied in topical, sublingual and intravenous forms across non-melanoma skin cancer, anogenital cancers, prostate and oesophageal cancer, with theranostic potential (therapeutic activation under 660nm red light and diagnostic fluorescence under 405nm violet light). In December 2025 Invion converted a patchwork of territory-limited licences from the technology's inventor group (RMW Cho Group) into a perpetual, exclusive global licence for a portfolio of "Agreed Indications" across human and animal health, paid in milestone-linked shares and royalties. The company operates a capital-light, partner-funded model — Hanlim Pharm (oesophageal, supported by a Korean government grant), SANGMYUNG Innovation (wet AMD) and Protect Animal Health (companion animal oncology) — but faces acute funding constraints, with A$0.59M cash at 30 June 2026 and a going-concern emphasis from its auditor.


Company's own description (paraphrased from FY2026 Annual Report)

In its FY2026 Directors' Report, Invion describes itself as a clinical-stage life-science company leading the global research and development of Photosoft™ technology for treating a range of cancers and infectious diseases in both human and animal health. It holds an expanded, perpetual and exclusive global licence to Photosoft™ carrying rights to develop, manufacture, market, distribute, sub-license and otherwise commercialise the technology for a defined portfolio of "Agreed Indications". The company states it partners with research institutes, notably the Peter MacCallum Cancer Centre (Peter Mac) and the Hudson Institute of Medical Research, to develop a novel photosensitiser intended to improve treatment of skin cancers and hard-to-treat solid tumours, with the aim of more effective targeting and killing of cancer cells with fewer side effects and minimal discomfort.

Independent characterisation

PeriodModelRevenue source
FY2018–FY2024Contract R&D service provider to the technology owner: RMWCG funded Photosoft™ cancer R&D in Australia/NZ under a 31 Aug 2017 R&D Services Agreement, with revenue recognised on a fully-burdened cost basisR&D services fees from RMWCG (A$3.29M FY2022; A$4.10M FY2023; A$3.69M FY2024)
FY2025Transitional; RMWCG stopped settling invoices; ~A$4.07M receivable fully providedNil revenue
FY2026 onwardGlobal licensee and platform out-licensor; partner-funded preclinical work; future royalties/sub-licensingNon-clinical research funding from Hanlim Pharm (A$384,707 in FY2026)

Invion is, in substance, a virtual biotech and IP-licensing vehicle. It owns no laboratories or manufacturing plants; R&D is executed through contract research organisations, clinical sites (Veracity Clinical Research and Cornerstone Dermatology in Queensland), academic partners (Peter Mac, Hudson Institute, University of Adelaide's ACARE) and outsourced chemistry/manufacturing providers. Its core asset is a licence (carried at A$7.46M on the balance sheet at 30 June 2026) to a photosensitiser library invented by Michael Honsue Cho, controller of RMW Cho Group Limited (RMWCG) and the newly formed licensor entity NGPDT IP (Holdings) Pty Ltd.

Business model evolution:

Revenue model mix (FY2026): 100% contract research/service funding from one customer (Hanlim Pharm Co., Ltd, South Korea). Product revenue: nil. Licensing/royalty income: nil to date. Subscription: not applicable.

Value chain position: Upstream drug discovery and early clinical development (preclinical to Phase I/II). Invion's strategy contemplates sub-licensing to pharmaceutical partners for late-stage development and commercialisation; under the prior territory licences a 50% sub-licence fee share was payable to RMWCG, while the new global licence provides for royalties on future net sales and certain sub-licensing or analogous payments (exact rates not publicly disclosed in the sources reviewed).

Customer types: (i) pharmaceutical and biotech partners (Hanlim Pharm, SANGMYUNG Innovation, Dr. I&B Co., Ltd., Protect Animal Health Inc.); (ii) historically, the technology licensor (RMWCG) as R&D services customer. Ultimately, end-users would be dermatologists, oncologists, ophthalmologists and veterinarians.

End-markets targeted: Non-melanoma skin cancer (SCC, BCC); anogenital cancers (anal, vulvar, penile); oesophageal cancer; prostate cancer; glioblastoma multiforme; HPV-related disease; wet age-related macular degeneration; companion-animal oncology; infectious diseases (antimicrobial-resistant bacteria, fungi, viruses); atherosclerosis; periodontal disease.

Strategy

Stated strategy themes (paraphrased from FY2025/FY2026 Annual Reports and announcements)

  1. Platform breadth via global licensing: Use the perpetual global licence for "Agreed Indications" — selected for attractive addressable markets and/or unmet need, with an eye to US FDA Orphan Drug Designation opportunities — as the basis for partnering and commercialisation.

  2. Disciplined, partner-funded development: Keep Invion's own spend focused on the relatively low-cost NMSC trial while other preclinical and clinical studies are subsidised or fully funded by partners, minimising dilution.

  3. Retain all IP: Every collaboration (Hanlim, SANGMYUNG, Protect, Dr. I&B) is structured so that Invion retains rights to Photosoft™ and any new IP arising.

  4. Clinical credibility: Strengthen clinical leadership (Hopper, Ramsay) and leverage leading institutions (Peter Mac, Hudson).

  5. Expand addressable markets: Move beyond human oncology into ophthalmology (wet AMD) and animal health (companion-animal cancer).

  6. Commercial transactions: Management's stated likely developments include expanding commercial partnerships with global healthcare companies and securing one or more commercial transactions for its drug assets.

Strategic initiatives — last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeFinancial terms / targets
16 Oct 2024100:1 share consolidationCapital structureReduce share count from ~6.8B to ~68M
FY2025Phase I/II NMSC trial launched (Queensland)ClinicalInvion-funded
FY2025Hanlim collaboration expanded to oesophageal cancer (plus GBM)PartnershipHanlim-funded preclinical
5 Jun 2025Formation of Photo Geni, Photo Derm, Photo Lung subsidiariesCorporateDormant vehicles
Jul 2025Loyalty options entitlement offer (underwritten by Blue Ocean Equities)FundingA$980,339 raised; 65.35M options at A$0.015, exercise A$0.14
Aug 2025FDA Orphan Drug Designation — INV043 in anal cancerRegulatory7-year US exclusivity post-approval; tax credits; fee waivers
Oct 2025Exit from Lind Partners facilityFunding / costA$1,145,990 repaid; no further obligations
21 Oct 2025Protect Animal Health collaborationNew marketProtect funds evaluation studies
18 Nov 2025Pharmbridge Pty Ltd formedCorporateHanlim contracting vehicle
Dec 2025Expanded perpetual exclusive global licenceTransformational IPUp to 36,705,966 shares in three clinical-milestone tranches + royalties; release of ~A$4.07M receivable claim
23 Dec 2025Hanlim / KDDF oesophageal cancer fundingNon-dilutive fundingUp to A$2M
30 Jan 2026Convertible note raise anchored by Chair and a major shareholderFunding~A$1.25M (A$1M committed by Chew and another major shareholder)
Feb 2026R&D tax-incentive financingFundingA$400k at 16% p.a.
19 May 2026SANGMYUNG wet AMD collaborationNew marketSANGMYUNG funds PoC studies
Q4 FY2026Clinical Advisor appointment (Dr Colin Hopper)Capability—
18 Aug 2026Board refresh: Paul Field (BD/licensing expertise)Governance—

ESG/sustainability commitments: None disclosed. Cost programs: No formal program with targets; management states it has "significant flexibility to delay or scale down R&D" to align with cash, and directors are deferring cash remuneration.

Medium-term financial targets / guidance

Not publicly disclosed. Invion provides no revenue, earnings or cash-burn guidance. It expects RDTI refunds (~A$539,520 claimed for FY2025, under ATO assessment) and states flexibility to finance against the FY2026 RDTI claim.

Products & Services

Invion has no marketed products. All entries below are development-stage programs within the single Photosoft™ segment. Pricing models are not publicly disclosed for any program.

Platform

Photosoft™ (Next Generation Photodynamic Therapy, NGPDT)

Description: A library of more than 300 unique photosensitiser compounds (SANGMYUNG announcement, 19 May 2026; FY2026 Annual Report). PDT uses a non-toxic photosensitiser that, when activated by light of a specific wavelength, generates reactive oxygen species that kill target cells and may stimulate anti-tumour immune responses.

Claimed differentiation: Improved tumour targeting; reduced pain versus existing PDT (clinicians reported no signs of pain in the NMSC trial); theranostic capability (treatment and diagnosis with one agent).

IP: Australian Patent No. 2021388872 extends protection to at least late 2041; earlier patents expire around 2033 (FY2023 Annual Report). IP legal ownership is being transferred from RMWCG to NGPDT IP (Holdings) Pty Ltd within 12 months of the December 2025 deal.

Licence status: Perpetual, exclusive, global for "Agreed Indications" (human and animal).

Lead drug candidate — INV043 (also designated HL270 in the Hanlim program)

Formulation / ProgramIndicationStage (latest)Key data / specificationsPartner / funderLatest milestone year
Topical INV043 ointmentNon-melanoma skin cancer — squamous cell carcinoma (SCC)Phase I/II adaptive platform protocol, QueenslandFirst six patients: no INV043-related adverse events; no pain reported; lesion-size reduction at 15 and 30 days after one cycle vs slight growth in untreated matched lesions; Part 2 adjusting drug-light interval; FY2026: tumour necrosis and lesion reduction (p<.05), complete resolution in select cases (durability under evaluation)Invion-funded (relatively low cost)FY2025–FY2026
Topical INV043 ointmentNMSC — basal cell carcinoma (BCC) cohortNewly authorised cohort after SRC approvalBCC ≈80% of skin cancer incidence (company statement)InvionFY2026
Topical INV043 + PD-1 inhibitorAnogenital cancers (anal, vulvar, penile)Trial in preparation at Peter Mac (ethics submission in preparation)Preclinical (mice): ~80% complete pathological response with INV043 + PD-1 vs 12.5% with PD-1 alone; US FDA Orphan Drug Designation (anal cancer), Aug 2025; A$20k CSSANZ Foundation grant to Prof Sandy HeriotPeter MacFY2025–FY2026
Sublingual INV043Prostate cancerInvestigator-led Phase II completed (sponsored by RMWCG)Six cycles, monotherapy; no serious adverse events; 40% positive response, 10% complete regression (RECIST 1.1); 44% PSMA-PET negative at 3 months; clinical study summary compiled by Scendea LimitedRMWCGResults Sep 2024
Intravenous INV043 (HL270)Oesophageal cancerPreclinical / IND-enabling; planned Australian first-in-human trialUp to A$2M funding; A$394,970 received to 30 Jun 2026Hanlim Pharm (KDDF grant)Dec 2025
INV043 (route not disclosed)Glioblastoma multiformePreclinicalPartner-funded studies; Invion retains IPHanlim PharmFY2024–FY2025
INV043 / diagnostic useSurgical margin delineation (theranostic)Exploratory in NMSC trial405nm violet light induces cancer-cell fluorescence; 660nm red light activates cytotoxicityInvionFY2025

Other Photosoft™ compounds and programs

ProgramIndicationStagePartnerNotes
OphthalmologyWet AMD and other retinal vascular diseasesProof-of-concept preclinical efficacy studiesSANGMYUNG Innovation Co., Ltd. (funds and conducts)First ophthalmology deal (19 May 2026); combines Photosoft with SANGMYUNG's ocular delivery technology
Companion animal oncologyCancer in petsIn vitro, in vivo and companion-animal evaluation studiesProtect Animal Health Inc. (TWSE/TPEx: 7850; funds and conducts)Signed Oct 2025; may lead to co-development agreement
HPVHPV-related diseasePreclinicalDr. I&B Co., Ltd.Initiated FY2024
Infectious diseasesMRSA, E. coli, Candida albicansIn vitroACARE, University of AdelaideFY2023 data
AntiviralZika, Dengue, SARS-CoV-2 (Delta, Omicron BA.1)In vitroIndependent labsNine of ten compounds showed activity vs SARS-CoV-2 variants (FY2023 Annual Report)
Periodontal diseaseGum diseaseEarly exploratory—Focus initiated FY2024
Solid tumours (breast, lung, ovarian)Including triple-negative breast cancerPreclinicalHudson InstitutePoC data supported INV043 selection
AtherosclerosisCardiovascularLicensed indication (prior APAC rights); no active program disclosed—Prior option for US/Canada/HK atherosclerosis rights at A$1M (superseded)

Legacy / divested assets

AssetStatus
INV102 (nadolol) — asthma, smoking cessation, COPDDemerged to Chronic Airway Therapeutics (2018)
INV104 (zafirlukast)Demerged to Chronic Airway Therapeutics (2018)
Cpn10 (CBio heritage) — lupus/autoimmuneDiscontinued; no further disclosure

Financial Narrative

Income statement

Sources: FY2023 Annual Report (FY2022–FY2023), FY2025 Annual Report (FY2024–FY2025), FY2026 Annual Report (FY2026). EBITDA and adjusted EPS computed (FY2022/FY2023 EPS restated for the 100:1 consolidation of 16 Oct 2024 using weighted shares of 6,117.4M and 6,419.6M ÷ 100). Finance costs relating to the Lind facility were classified within administrative expenses in FY2024 (A$240,000) and FY2025 (A$694,775); FY2026 administrative expenses include A$993,060 "Lind administrative cost" plus separately reported finance costs of A$346,796 and a derivative fair-value gain of A$376,924.

Margins and growth

Gross profit/gross margin: Invion does not report cost of sales; its service revenue was recognised on a cost-plus/fully-burdened basis, so a gross margin is not meaningful (aggregators such as Simply Wall St display gross profit equal to revenue). Revenue CAGR FY2022–FY2026: −41.5% (computed), though this is distorted by the change of revenue counterparty and should not be read as an operating trend.

Commentary. The P&L divides into two eras. Through FY2024, Invion was effectively a cost-reimbursed contractor to RMWCG: revenue of A$3.3–4.1M offset most R&D spend, and statutory losses were modest (A$1.6–2.2M) apart from FY2024. The inflection came in FY2024, when RMWCG stopped paying; Invion recognised a ~A$3.7M impairment through the P&L (notes cite a A$4.07M expected-credit-loss allowance — see discrepancy note below), turning a ~A$1.9M underlying loss into A$5.6M. FY2025 had no revenue and was further burdened by a sharp acceleration of licence amortisation (A$4.8M) after management cut the licences' assessed useful life from 20 years to 10 years — a non-cash but material signal about expected economic life. FY2026's loss narrowed to A$5.6M as amortisation normalised (A$1.7M) and Hanlim-funded revenue resumed, but cash-relevant overheads rose: administrative expenses of A$2.1M exceed R&D (A$1.5M), inflated by Lind facility costs (A$1.0M) — an unfavourable mix for a development company.

Half-year snapshot (H1 FY2026, six months to 31 Dec 2025)

Source: Appendix 4D lodged 27 Feb 2026 (via InvestSMART summary). The review report carried an emphasis on going concern.

Balance sheet

Sources: Annual Reports. Net debt and working capital computed. FY2026 "borrowings" comprise R&D financing A$425,956 (A$400,000 principal at 16% p.a. plus accrued interest), convertible-note host liability A$1,100,967 and derivative liability A$20,638. Convertible notes mature 5 Mar 2029 but are classified as current (conversion feature).

Commentary. The balance sheet has been eroded from A$19.6M equity (FY2022) to A$5.3M (FY2026), with intangibles now 91% of total assets and net tangible assets negative (−1.96 cents per share at 30 Jun 2026). Cash fell from A$8.5M after the FY2022 raisings to A$0.59M; working capital swung negative in FY2025. Management notes that A$408,742 of current liabilities are unpaid salaries and director fees owed to current directors, and A$1.12M relates to convertible notes requiring no cash settlement — excluding those, the adjusted net current liability position is ~A$0.62M (FY2026 Annual Report, going-concern note). Accumulated losses of A$148.8M against A$152.6M of contributed capital show that nearly all capital raised over 25 years (much of it under the CBio/Inverseon strategy) has been consumed.

Cash flow

Sources: Annual Reports; FCF computed. FY2025 "debt proceeds" = receipts from Lind Partners; FY2026 = net borrowings A$1,985,827 (convertible notes) plus R&D financing A$400,000. FY2026 operating receipts from customers were A$384,413 (Hanlim).

Commentary. Underlying operating burn has been steady at A$2.4–3.0M per year since FY2024 — modest in absolute terms but large relative to a A$4M market capitalisation and A$0.59M cash. Between FY2022 and FY2024, Invion spent A$10.65M of shareholders' cash on territory licence payments to RMWCG (a related-party associate) — more than three years of operating burn. Those payments were capitalised, then amortised at an accelerated rate, and ultimately superseded by the December 2025 global licence. FY2026 financing relied on listed loyalty options (A$0.98M), convertible notes (A$2.03M gross across Oct 2025 and Mar/Jun 2026) and R&D tax-incentive pre-funding (A$0.4M), with A$1.15M used to exit the Lind facility.

Ratios

All computed from Annual Report data. Net debt/EBITDA and interest coverage are not meaningful (negative EBITDA; FY2026 finance costs A$346,796 against operating loss of A$5.66M). Cash conversion cycle not meaningful (no inventory; receivables fully impaired; service revenue).

Trend summary. Every return metric deteriorated from FY2023 to FY2025 and remained deeply negative in FY2026. Liquidity ratios show the clearest stress: the current ratio fell from 18.7x to 0.24x in four years. The company's first financial debt appeared in FY2026, albeit structured as equity-convertible.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipIncorporatedFunction (as disclosed or inferred)

Invion Limited

Parent (listed)

2000

Holds Photosoft™ licence; contracts R&D

EpiTech Dermal Science Pty Ltd (formerly IVX Cosmetics Pty Ltd)

100%

Pre-FY2022

Dermal/cosmetic application vehicle; no disclosed operations

Photo Geni Pty Ltd

100%

5 Jun 2025

Dormant at 30 Jun 2025; name suggests anogenital indication vehicle (inference)

Photo Derm Pty Ltd

100%

5 Jun 2025

Dormant; name suggests dermatology vehicle (inference)

Photo Lung Pty Ltd

100%

5 Jun 2025

Dormant; name suggests lung cancer vehicle (inference)

Pharmbridge Pty Ltd

100%

18 Nov 2025

Contracting party for the Hanlim oesophageal cancer research funding agreement

Results by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Segment revenue — Photosoft drug development (AUD K)

3,2924,1053,6940385

Segment operating profit/loss (AUD K)

-2,241-1,615-5,628-8,808-5,663

Segment pre-tax profit/loss (AUD K)

-2,241-1,615-5,628-8,808-5,633

Segment operating margin (%)

-68.1-39.3-152.3—-1,472.1

Revenue YoY growth (%)

—24.7-10.0-100.0—

Contribution to group revenue (%)

100100100—100

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD K)

3,2924,1053,6940385

Other income incl. interest (AUD K)

80344931

Employee benefits expense (AUD K)

748710588592527

Research and development expense (AUD K)

2,3232,8982,6911,2901,483

Administrative and corporate expense (AUD K)

1,1611,0911,3462,0192,118

Share-based payment expense (AUD K)

95937123494199

Depreciation and amortisation (AUD K)

4226838164,8151,722

Impairment of receivables (AUD K)

003,69700

Operating profit/loss (AUD K)

-2,241-1,615-5,628-8,808-5,663

EBITDA (AUD K)

-1,819-932-4,812-3,993-3,941

Net finance items incl. derivative fair value gain (AUD K)

000030

Pre-tax profit/loss (AUD K)

-2,241-1,615-5,628-8,808-5,633

Income tax (AUD K)

00000

Net profit/loss (AUD K)

-2,241-1,615-5,628-8,808-5,633

Basic EPS as reported (AUD cents)

-0.04-0.03-8.76-12.22-6.26

Basic EPS consolidation-adjusted (AUD cents)

-3.66-2.52-8.76-12.22-6.26

Diluted EPS (AUD cents, consolidation-adjusted)

-3.66-2.52-8.76-12.22-6.26

Dividends per share (AUD cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating margin (%)

-68.1-39.3-152.3—-1,472.1

EBITDA margin (%)

-55.3-22.7-130.3—-1,024.4

Net margin (%)

-68.1-39.3-152.3—-1,464.2

Revenue YoY growth (%)

—24.7-10.0-100.0—

Balance Sheet (AUD)

ItemH1 FY2026H1 FY2025

Loss after tax (AUD)

3,565,8361,872,230

Total assets at period end (AUD)

8,088,461—

Net assets at period end (AUD)

5,706,180—

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

20,04119,04715,4519,4898,167

Cash and cash equivalents (AUD K)

8,4734,085784850592

Total current assets (AUD K)

8,6485,7612,081933697

Intangibles — Photosoft licences (AUD K)

11,39313,22813,3318,5357,464

Goodwill (AUD K)

00000

Total current liabilities (AUD K)

4626511,0141,2382,847

Short-term debt (AUD K)

00001,548

Long-term debt (AUD K)

00000

Total debt (AUD K)

00001,548

Net debt (AUD K)

-8,473-4,085-784-850955

Total equity (AUD K)

19,57918,39614,4388,2515,320

Working capital (AUD K)

8,1855,1101,067-305-2,149

Issued capital (AUD K)

146,544146,883148,355151,207152,596

Accumulated losses (AUD K)

-130,836-130,475-136,080-144,541-148,806

Shares on issue, consolidation-adjusted (millions)

64.1764.2266.0584.88109.20

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K)

-1,109-1,813-2,401-2,969-2,374

Payments for licences / intangibles (AUD K)

-7,250-2,500-9000-65

Payments for property, plant and equipment (AUD K)

0-7600-4

Free cash flow after all capex (AUD K)

-8,359-4,389-3,301-2,969-2,442

Free cash flow excluding licence payments (AUD K)

-1,109-1,889-2,401-2,969-2,378

Net financing cash flow (AUD K)

15,796003,0362,184

Gross equity proceeds incl. listed options (AUD K)

16,638002,500980

Debt and quasi-debt proceeds (AUD K)

0001,4502,386

Debt repayments (AUD K)

000-744-1,146

Dividends paid (AUD K)

00000

Share buybacks (AUD K)

00000

Net change in cash (AUD K)

7,437-4,389-3,30167-258

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Return on equity, year-end equity (%)

-11.4-8.8-39.0-106.7-105.9

Return on assets, year-end assets (%)

-11.2-8.5-36.4-92.8-69.0

ROIC, operating loss / (equity + debt − cash) (%)

-20.2-11.3-41.2-119.0-90.2

Current ratio (x)

18.708.852.050.750.24

Debt to equity (x)

00000.29

Asset turnover (x)

0.160.220.240.000.05

R&D expense / revenue (%)

70.670.672.8—385.4

Revenue by Region

RegionFY2022FY2023FY2024FY2025FY2026

Hong Kong — RMW Cho Group, R&D services (AUD K)

3,2924,1053,69400

South Korea — Hanlim Pharm, non-clinical research (AUD K)

0000385

Australia (AUD K)

00000

Total revenue (AUD K)

3,2924,1053,6940385

Growth by region (%)

Growth by region (%)FY2023FY2024FY2025FY2026

Hong Kong YoY (%)

24.7-10.0-100.0

n/m

South Korea YoY (%)

———

new

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.900.400.400.110.04

Market capitalisation at 30 June (AUD Mn)

57.725.726.49.34.4

Shares on issue at 30 June (millions)

64.1764.2266.0584.88109.20

Change by Horizon

HorizonChangeBasis

Calendar YTD to 24 Sep 2026

−59.1%

MarketScreener

1-year (to Aug 2026)

−58.3%

Investing.com

3-year (30 Jun 2023 A$0.40 → ~A$0.038)

≈ −90%

Computed

5-year (30 Jun 2021 A$1.30 → ~A$0.038)

≈ −97%

Computed

52-week range

A$0.032 – A$0.20

Investing.com

Valuation Multiples

MultipleInvionPeer note

Market cap

~A$4.2M

—

Enterprise value

~A$5.1–5.2M (computed: market cap + A$1.55M debt − A$0.59M cash; MarketScreener A$5.21M)

—

P/E

Negative (n/m); MarketScreener cites −0.56x FY2026

Peers: Biofrontera loss-making; Photocure near breakeven

EV/EBITDA

n/m (negative EBITDA)

—

EV/Sales (FY2026)

~13x (computed); MarketScreener 12.4x

—

P/B

~0.78x (computed on A$5.32M equity); negative price/tangible book

—

Capital Instruments

InstrumentFace / carryingRateMaturity / repaymentNotes

R&D tax-incentive financing

A$400,000 principal; A$425,956 incl. interest

16% p.a.

On receipt of FY2025 RDTI refund (~A$539,520 claimed)

Short-dated

Convertible notes (Mar/Jun 2026)

A$1,250,000 face; A$1,100,967 host + A$20,638 derivative

0% coupon (unsecured)

5 Mar 2029

Conversion at 80% of 15-day VWAP (floor/cap terms per offer documents not fully retrieved); A$244,000 held indirectly by the Chair

Securities on Issue

SecurityNumberExercise priceExpiry

Listed options (IVXO)

65,894,631

A$0.14

30 Jun 2027

Broker listed options

1,564,508

stated as A$0.004 in AR (likely typographical; same class as IVXO)

30 Jun 2027

Placement options

14,825,716

A$0.28

12 May 2028

Director fee options

4,928,643 (+ other nil-priced 454,036)

Nil

2028–2029

Director incentive options

3,177,324

A$0.086

11 Jun 2029

Blue Ocean advisory options

2,551,724

A$0.14 / A$0.488

2028

Other unlisted options

~2,535,151

A$0.12–A$1.70

2026–2028

Licence milestone shares (contingent)

24,470,644

Nil

On clinical milestones

Analyst Conclusions

Management guidance

No quantitative guidance. Management's qualitative outlook (FY2026 AR) centres on reaching clinical and commercial milestones for Photosoft™, expanding partnerships with global healthcare companies, and securing commercial transactions. Consensus growth expectations: none (no coverage).

Bull case

  1. Option value of a global platform at a micro-cap price: For ~A$5M EV, investors gain exposure to a perpetual global licence over >300 photosensitisers with patent life to ~2041, FDA ODD in anal cancer and early efficacy signals in prostate (40% response) and NMSC (p<.05 lesion reduction).

  2. Capital-light, partner-funded pipeline: Hanlim (up to A$2M with Korean government backing), SANGMYUNG and Protect fund multiple programs while Invion keeps all IP — any one producing a co-development or licence deal could re-rate the stock materially relative to its A$4M market value.

  3. Aligned insiders and improving structure: The Chair (~21.5% interest) personally backed the January 2026 notes, defers salary, and the Lind facility has been removed; adding a licensing-experienced independent director signals an imminent partnering push.

Bear case

  1. Existential funding gap: A$0.59M cash against ~A$2.4M annual burn, negative working capital (−A$2.15M) and an auditor's going-concern flag imply near-term, highly dilutive raises at depressed prices (CN conversions already occurred at A$0.07 vs A$0.14 placements a year earlier).

  2. Governance and related-party concentration: Combined Chair/CEO, one independent director, a licensor associated with the CEO's investment firm, and A$10.65M previously paid for licences later superseded — minority shareholders bear the cost of the RMWCG relationship.

  3. Thin, early data in competitive markets: Open-label, small-n results face approved PDT systems (Ameluz, Levulan, Metvix) and anti-VEGF incumbents; Phase II/III costs are far beyond Invion's balance sheet, so value depends on a partner willing to pay.

Key catalysts and monitorables (next 12 months)

  • September 2026 quarter Appendix 4C (by 31 Oct 2026): cash, burn and any new funding.

  • AGM on 25 Nov 2026: capital-raising approvals (placement capacity, option issues).

  • Receipt of the FY2025 RDTI refund (~A$539,520) and repayment of the 16% R&D loan; lodgement/financing of the FY2026 claim.

  • NMSC trial: BCC cohort readouts and durability of complete responses.

  • Peter Mac anogenital trial: ethics approval and first patient dosed.

  • Hanlim/KDDF: completion of non-clinical package toward Australian IV INV043 first-in-human trial; potential trigger toward licence milestone 2 (IND-enabled Phase II start) over a longer horizon.

  • IP transfer from RMWCG to NGPDT IP (due within 12 months of the Dec 2025 deal).

  • SANGMYUNG wet AMD and Protect companion-animal PoC data; conversion into co-development agreements.

  • Progress of RDTI reform legislation.

  • Any sub-licensing transaction led by the refreshed board.

Concluding analyst verdict

Invion Limited is best understood as a heavily discounted call option on the Photosoft™ photosensitiser platform, held inside a balance sheet that cannot fund its own exercise. The December 2025 global licence materially improved the quality of the asset: it replaced a fragmented, cash-hungry web of territory licences with perpetual worldwide rights for selected human and animal indications, deferred most consideration into clinical-milestone shares, released the dysfunctional R&D services relationship with RMW Cho Group, and secured a founder guarantee pending IP transfer. Scientific signals are encouraging but immature — clean topical safety, statistically significant lesion reduction in NMSC, notable prostate responses in a licensor-run Phase II, and striking preclinical synergy with PD-1 inhibitors that earned FDA orphan status in anal cancer.

Against this, the financial position is precarious. With A$0.59 million of cash at 30 June 2026, roughly A$2.4 million of annual operating burn, negative working capital, an auditor's going-concern paragraph and a share price down about 97% over five years, Invion's immediate value driver is not science but financing. The next equity raise is likely to be priced near current levels and could materially dilute holders, compounded by a large options overhang and up to 24.5 million further licence shares. Governance — a combined Chair/CEO, a board with limited independence, and the CEO's investment firm being an associate of the licensor — warrants a discount and close scrutiny of any further related-party transactions.

The investment case therefore hinges on whether management can convert its partner-funded collaborations (Hanlim, SANGMYUNG, Protect) and the newly appointed licensing expertise into a cash-generating sub-licence before balance-sheet pressure forces punitive dilution. For risk-tolerant, specialist investors, the asymmetry is real; for most institutional mandates, Invion remains uninvestable until funding is secured and a third-party validation transaction is executed. Stance: Speculative / High Risk — monitor for a partnering transaction and recapitalisation terms.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointed / tenurePrior rolesEducation

Prof. Thian Chew

Executive Chairman and CEO

Executive Chair & CEO since 31 Oct 2020; associated with Invion since 2017

Managing Partner, Polar Ventures (since c.2013); co-founder, Chronic Airway Therapeutics; Executive Director, Goldman Sachs (New York, Hong Kong); Consultant Project Manager, Morgan Stanley; Director, KPMG Consulting (Singapore, Sydney); Senior Manager, KPMG (Taipei, Melbourne); Adjunct Associate Professor, HKUST; Visiting Professor, UCL Global Business School for Health; Advisory Board, Stanford Medicine CARE

MBA, Wharton (Palmer Scholar); MA, Lauder Institute (UPenn); B. Information Systems, Monash; Chartered Accountant

Alan Yamashita

Non-Executive Director; Chair, Nomination & Remuneration Committee; Member, Audit & Risk Committee

—

Managing Partner, Polar Ventures; 16-year Goldman Sachs veteran; MD & Head of Asia Capital Markets, Merrill Lynch (1996–98); President & CEO, Search Investment Group (1999–2005)

MPA, BA

Melanie Leydin

Non-Executive Director, Company Secretary and CFO

NED since 31 Aug 2024; Company Secretary since 28 Oct 2024

Principal, Leydin Freyer (2000–2021, acquired by Vistra); EVP Global Solutions SE Asia, Vistra; director of Imagion Biosystems (ASX: IBX); former director of Unico Silver, Alchemia, Medibio

BBus (Acc. & Corp Law), FCA, FGIA

Paul Field

Independent Non-Executive Director

Since 18 Aug 2026

30+ years in global biopharma business development, licensing and co-development; NED of 60 Degrees Pharmaceuticals (NASDAQ: SXTP)

BA (Hons), MA, FAICD

Alistair Bennallack

Former NED; former Chair, Audit & Risk Committee

Resigned 18 Aug 2026

COO/CFO, Village Roadshow Pty Ltd; CEO, Village Roadshow Theme Parks Asia

CA

Rob Merriel

Former NED

Resigned 31 Aug 2024

CFO, Chief Commercialisation Officer & Company Secretary, Hudson Institute

BA, Grad Dips, CPA

Directors' Remuneration

NameSalary & feesCash bonusSuperLong service leaveEquity-settled SBPTotal

Thian Chew

354,0000023,76970,777448,546

Alan Yamashita

27,37000024,96752,337

Alistair Bennallack

27,37000024,96752,337

Melanie Leydin

60,000000060,000

Total

468,740

0

0

23,769

120,711

613,220

Directors' Remuneration (Annual)

MetricFY2022FY2023FY2024FY2025FY2026

Total KMP remuneration (AUD K)

1,6891,022674618613

CEO total remuneration (AUD K)

1,503851510440449

CEO cash bonus (AUD K)

161123000

Board & Management Changes

DateChangeContext

31 Jul 2024

Claire Newstead-Sinclair resigns as Company Secretary; Tai Phan appointed

Vistra team reassignment

31 Aug 2024

Rob Merriel resigns; Melanie Leydin appointed NED

Hudson-linked director departs

28 Oct 2024

Leydin appointed Company Secretary (replacing Phan)

Vistra reassignment

Dec 2024

Prof Robert Ramsay appointed Scientific Advisor

Anogenital program support

Q4 FY2026

Dr Colin Hopper appointed Clinical Advisor

Strengthen clinical governance, trial design

18 Aug 2026

Paul Field appointed Independent NED; Alistair Bennallack resigns

Adds BD/licensing expertise consistent with out-licensing strategy

Major Shareholders

HolderShares% of 109.2M (computed)Source / date

Thian Chew — total relevant interest (direct 246,706; indirect 23,192,537, including Polar Ventures and the 12,235,322 RMWC Pty Ltd consideration shares deemed associated)

23,439,24321.5

FY2026 Annual Report

RMWC Pty Ltd (RMW Cho Group) — licence consideration shares (escrowed 12 months from 12 Jun 2026) — included in Chew's relevant interest

12,235,32211.2

FY2026 Annual Report

Polar Ventures Limited (older register)

5,452,178

8.20 (as reported, ~66M share base)

Motley Fool AU (date not specified; likely late 2024)

NGPDT Greater China Limited (older register)

2,726,523

4.10 (as reported)

Motley Fool AU

Citicorp Nominees Pty Limited (older register)

2,468,145

3.00 (as reported; arithmetically ~3.7% on the same base — discrepancy)

Motley Fool AU

Alistair Bennallack (former director)

248,1100.2

FY2026 Annual Report

Alan Yamashita

150,0530.1

FY2026 Annual Report

Competitive Landscape

Competitors by Segment

ProgramCompetitorProduct / approachPositioning vs Invion

NMSC / dermatology PDT

Biofrontera Inc. (NASDAQ: BFRI)

Ameluz® (aminolevulinic acid gel) + RhodoLED® lamp; sNDA for superficial BCC accepted by FDA

Commercial-stage, US$41.7M revenue (FY2025); entrenched in dermatology PDT

NMSC / dermatology PDT

Sun Pharmaceutical

Levulan® Kerastick® + BLU-U® (ALA)

Large-cap incumbent in AK PDT

NMSC / dermatology PDT

Galderma

Metvix® / methyl aminolevulinate PDT (ex-US)

Global dermatology leader

Advanced cSCC / BCC systemic

Regeneron / Sanofi

Libtayo® (cemiplimab)

Standard of care in advanced disease

Advanced BCC

Roche (Erivedge®); Sun Pharma (Odomzo®)

Hedgehog inhibitors

Systemic alternatives

Bladder cancer PDD/PDT

Photocure ASA (OSE: PHO)

Hexvix®/Cysview® blue-light cystoscopy

Commercial PDD peer; NOK 532.6M revenue (FY2025)

Oncology PDT (NMIBC)

Theralase Technologies (TSXV: TLT)

Ruvidar™ (TLD-1433) PDT

—

Vascular-targeted PDT

Steba Biotech (private)

TOOKAD® (padeliporfin) for prostate cancer

Approved in some markets (EU)

Oncology PDT

Pinnacle Biologics

Photofrin® (porfimer sodium) — oesophageal and lung cancer

Legacy PDT incumbent in oesophageal indication

Photoimmunotherapy

Rakuten Medical (private)

Akalux® (cetuximab sarotalocan), head & neck

Next-gen light-activated oncology

Oesophageal systemic

BMS (Opdivo®), Merck (Keytruda®)

PD-1 inhibitors

Standard of care; Invion positions PDT as complementary

Wet AMD

Regeneron (Eylea®), Roche (Vabysmo®), Novartis/Bausch (Visudyne® verteporfin PDT)

Anti-VEGF; legacy PDT

Dominant incumbents

Companion-animal oncology

Zoetis, Elanco, Boehringer Ingelheim Animal Health

Veterinary oncology products

Large incumbents

Peer Comparison FY2026

MetricInvion (FY2026, Jun)Biofrontera Inc. (FY2025, Dec)Photocure ASA (FY2025, Dec)

Revenue

A$0.38M

US$41.7M

NOK 532.6M

Revenue growth

n/m (from nil)

+12%

Hexvix/Cysview product revenue ~+10% (9% incl. FX)

Gross margin

n/m

73.7%—

Net result

Loss A$5.63M

Loss US$10.5M

Approx. loss NOK 1.5M (aggregator)

Adjusted EBITDA

−A$3.94M (computed)

−US$10.6M

Commercial EBITDA NOK 55.9M

R&D intensity

385% of revenue

——

Stage

Phase I/II

Commercial

Commercial

Company Snapshot

$0.2M

Revenue

2000

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Global perpetual exclusive licence for Agreed Indications in human and animal health, secured Dec 2025 and approved 29 May 2026, with most consideration deferred into clinical-milestone shares (FY2026 AR).
  • Patent runway to ~2041 via Australian Patent No. 2021388872 covering INV043 (FY2023 AR).
  • Clean early safety signal: no INV043-related adverse events in the first six NMSC patients; no pain reported (FY2025 AR).
  • Clinical efficacy signals: prostate Phase II — 40% response, 10% complete regression (RECIST 1.1), 44% PSMA-PET negative at 3 months (FY2025 AR); NMSC lesion reduction p<.05 (FY2026 AR).
  • Regulatory validation: FDA Orphan Drug Designation in anal cancer (Aug 2025).
  • Non-dilutive funding: up to A$2M (Hanlim/KDDF) plus partner-funded SANGMYUNG, Protect and Dr. I&B programs; A$384,707 FY2026 revenue (FY2026 AR).

Weaknesses

  • Critical liquidity: cash A$592,311 at 30 Jun 2026 versus annual operating outflow of A$2.37M (FY2026 AR).
  • Going-concern uncertainty flagged by the auditor in FY2025, H1 FY2026 and FY2026.
  • Negative working capital of A$2.15M and current ratio of 0.24x (computed, FY2026).
  • Overhead-heavy cost mix: administrative expense (A$2.12M) exceeds R&D (A$1.48M) in FY2026, inflated by A$0.99M Lind costs.
  • Value destruction track record: A$10.65M of licence payments (FY2022–FY2024) superseded and partly written down via accelerated amortisation; accumulated losses A$148.8M.
  • Governance concentration: combined Chair/CEO; only one independent director; related-party associations between the CEO's Polar Ventures and the licensor.

Opportunities

  • Sub-licensing of Agreed Indications to larger pharma, with Paul Field's licensing experience added to the board (Aug 2026).
  • Anogenital trial with Peter Mac leveraging ODD; combination with blockbuster PD-1 inhibitors.
  • Oesophageal IV program toward an Australian first-in-human trial, Hanlim-funded; market ~US$15.3B (2025).
  • Wet AMD (~US$11B market) via SANGMYUNG's ocular delivery technology.
  • Companion-animal oncology via Protect, a potentially faster regulatory path.
  • RDTI refunds (~A$539,520 FY2025 claim under assessment) and potential FY2026 claim.

Threats

  • Dilution risk: 67.46M listed options (A$0.14) and 28.47M unlisted options outstanding, plus up to 24.47M further licence shares — fully diluted share count ~229M (computed).
  • RDTI reform proposed in the 12 May 2026 Federal Budget could remove refundability for entities over 10 years old from FY2029.
  • Licensor execution risk: IP transfer from RMWCG to NGPDT IP pending; prior history of RMWCG non-payment of ~A$4.07M.
  • Competition from approved PDT systems (Ameluz, Levulan, Metvix) and anti-VEGF incumbents in wet AMD.
  • Clinical failure risk in small, uncontrolled studies.
  • Share price collapse: −59% calendar YTD to 24 Sep 2026 and ~97% decline over five years (MarketScreener; computed), constraining equity raising.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Lind Share Subscription Agreement terminated; A$505k refundedBegins exit from costly structured financing
9 May 2025Virtual Extraordinary General MeetingApprovals related to placement securities (TipRanks)
5 Jun 2025Photo Geni, Photo Derm, Photo Lung subsidiaries incorporatedIndication-specific vehicles for potential partnering
13 Jun 2025Fully underwritten loyalty options entitlement offer announcedLow-dilution funding instrument
Jul 2025Loyalty offer closes, raising A$980,339Funds NMSC trial
23 Jul 2025540,000 shares and options issued to Blue Ocean (6% fee)Underwriting cost
28 Jul 2025344,620 vendor options issued in lieu of servicesCash conservation
Aug 2025FDA Orphan Drug Designation for INV043 in anal cancerFirst US regulatory designation
27 Aug 2025FY2025 results: loss A$8.81M; zero revenue; going-concern emphasisHighlights RMWCG non-payment
23–24 Sep 20251,384,886 CEO options (A$1.70) expire unexercisedOverhang reduction
10 Oct 2025Repayment of Lind facility with capital raiseRemoves Lind overhang
21 Oct 2025Protect Animal Health collaborationAnimal health entry
31 Oct 202572,024 convertible notes issued (A$782,254); September quarter 4CBridge funding
18 Nov 2025Pharmbridge Pty Ltd incorporatedHanlim vehicle
26 Nov 2025AGM; remuneration report 93.62% supportShareholder backing
Dec 2025Expanded global perpetual exclusive licence securedTransformational for IP position
23 Dec 2025Hanlim / KDDF up to A$2M oesophageal funding announcedNon-dilutive validation
13 Jan 2026300,000 options (A$1.50) ceaseHousekeeping
30 Jan 2026~A$1.25–1.3M convertible note raise, A$1M from Chew and another major holderInsider support
Feb 2026A$400k R&D financing at 16% p.a.Expensive bridge against RDTI
19 Feb 2026Emergence 2026 investor presentationInvestor outreach
27 Feb 2026H1 FY2026 loss A$3.57M (vs A$1.87M)Burn and finance costs rising
5 Mar 2026Oct 2025 notes convert into 11,318,060 shares at A$0.07 (floor price, licence not yet unconditional by 28 Feb); tranche 1 of new notes (A$578,118)Dilution at low price
11 Mar 2026200,000 employee options (A$0.12)—
18–23 Mar 2026Proposed securities issues (incl. 5M shares subject to holder approval)Pipeline of approvals
22 Apr 2026Bionnova 2026 investor presentationInvestor outreach
1 May 2026200,000 options (A$1.00) ceaseHousekeeping
12 May 2026Federal Budget proposes RDTI reforms (from FY starting 1 Jul 2028), including limiting refundable offset to entities under 10 years oldMaterial long-term funding risk (Invion is ~26 years old)
19 May 2026SANGMYUNG wet AMD collaboration; shares surged on the day (Kalkine)Ophthalmology entry
22 May 2026CEO presents at Wholesale Investor Capital2026 (Sydney)Investor outreach
29 May 2026Shareholders approve global licenceLicence becomes unconditional
12 Jun 202612,235,322 consideration shares issued; 4.93M director fee options and 3.18M incentive options grantedLicence tranche 1; remuneration in equity
16 Jun 2026Tranche 2 convertible notes (A$671,882)Completes Jan 2026 raise
19 Jun 20262.55M advisory options to Blue Ocean; 1.56M broker optionsAdvisory cost
31 Jul 2026June quarter 4C: cash A$592k; Hopper appointment; SANGMYUNG; NMSC progressLiquidity alarm
18–19 Aug 2026Paul Field joins board; Bennallack resignsBD capability added
25–26 Aug 2026FY2026 results; auditor flags going-concern material uncertaintyFunding need confirmed
Scheduled 25 Nov 2026Annual General MeetingUpcoming

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from AUD 3.3 Mn in FY2022 to AUD 0.4 Mn in FY2026.
Invion Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue3.34.13.700.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Invion Limited, Annual Report for the year ended 30 June 2026 (Appendix 4E), lodged 26 Aug 2026 — via bulletin.webull.com (ASX announcement mirror)
  2. Invion Limited, Annual Report for the year ended 30 June 2025 (Appendix 4E), lodged 27 Aug 2025 (announcements.asx.com.au)
  3. Invion Limited, Annual Report for the year ended 30 June 2023, lodged 28 Sep 2023 (announcements.asx.com.au)
  4. Invion Limited, Appendix 4D Half-Year Report to 31 Dec 2025 (27 Feb 2026) — InvestSMART summary; bulletin.webull.com
  5. Invion ASX announcement, "Major Shareholders Lead Invion's Strongly Supported $1.3M Capital Raise", 30 Jan 2026 — announcements.asx.com.au
  6. Invion ASX announcement, SANGMYUNG Innovation collaboration, 19 May 2026 — announcements.asx.com.au; InvestorPA; StockWire; Kalkine Media
  7. Invion Appendix 4C and Quarterly Activities Report, June 2026 quarter, 31 Jul 2026 — InvestorPA; InvestSMART
  8. InvestSMART IVX announcements listings (2025–2026)
  9. MarketScreener — Invion Limited quote and news log (Sep 2026)
  10. Investing.com — Invion Ltd (IVX) quote page (Aug 2026)
  11. Stockopedia — IVX income statement summary
  12. Simply Wall St — ASX:IVX profile
  13. TipRanks — IVX/IVIXF pages and announcement summaries
  14. TradingView / GuruFocus — ISIN, IPO date, FIGI
  15. PitchBook — Invion profile
  16. IBISWorld — Invion Limited company profile
  17. The Motley Fool Australia — ASX:IVX ticker page (shareholder snapshot)
  18. BioCentury (Sep 2012); BioSpectrum Asia (Jul 2012; Sep 2018); LabOnline (Jul 2012); BioWorld — CBio/Inverseon merger and CAT demerger
  19. ShareCafe (21 Oct 2025) — Protect Animal Health collaboration
  20. Biofrontera Inc. — FY2025 results release (19 Mar 2026) and SEC 8-K exhibits
  21. Photocure ASA — Q4 and full-year 2025 results (18 Feb 2026); financialfilings.com summary

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.